Emergent BioSolutions Inc. (EBS)

Market Cap	101.80M
Revenue (ttm)	1.05B
Net Income (ttm)	-760.50M
Shares Out	52.20M
EPS (ttm)	-14.85
PE Ratio	n/a
Forward PE	7.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,083,913
Open	2.120
Previous Close	2.180
Day's Range	1.950 - 2.128
52-Week Range	1.420 - 10.880
Beta	1.19
Analysts	Buy
Price Target	5.00 (+156.41%)
Earnings Date	May 1, 2024

About EBS

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 15, 2006
• Employees: 1,600
• Stock Exchange: NYSE
• Ticker Symbol: EBS

Financial Performance

In 2023, EBS's revenue was $1.05 billion, a decrease of -6.10% compared to the previous year's $1.12 billion. Losses were -$760.50 million, 259.4% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for EBS stock is "Buy." The 12-month stock price forecast is $5.0, which is an increase of 156.41% from the latest price.

Price Target

$5.0

(156.41% upside)

Analyst Consensus: Buy